Results 211 to 220 of about 14,687 (252)

Physiologically Based Pharmacokinetic (PBPK) Modeling in Children

Clinical Pharmacology & Therapeutics, 2012
This review summarizes the present status of physiologically based pharmacokinetic (PBPK) modeling and simulation (M&S) and its application in support of pediatric drug research. We address the reasons that PBPK is suited to the current needs of pediatric drug development and pharmacotherapy in light of the evolution in pediatric PBPK methodologies and
J S, Barrett, O, Della Casa Alberighi, S, Läer, B, Meibohm   +3 more
openaire   +2 more sources

PBPK Modeling Advances Understanding of D4 Pharmacokinetics

Toxicological Sciences, 2003
The article highlighted in this issue is Physiological Modeling of Inhalation Kinetics of Octamethylcyclotetrasiloxane in Humans during Rest and Exercise, by Micaela B. Reddy, Melvin E. Andersen, Paul E. Morrow, Ivan D. Dobrev, Sudarsanan Varaprath, Kathleen P. Plotzke, and Mark J. Utell (pp. 43-56).
openaire   +2 more sources

PBPK modeling of irbesartan: incorporation of hepatic uptake

Biopharmaceutics & Drug Disposition, 2015
AbstractPhysiological based pharmacokinetic (PBPK) modeling is now commonly used in drug development to integrate human or animal physiological data in order to predict pharmacokinetic profiles. The aim of this work was to construct and refine a PBPK model of irbesartan taking into account its active uptake via OATP1B1/B3 in order to predict more ...
Helene, Chapy, Sylvie, Klieber, Priscilla, Brun, Sabine, Gerbal-Chaloin, Xavier, Boulenc, Olivier, Nicolas   +5 more
openaire   +2 more sources

PBPK in Preterm and Term Neonates: A Review

Current Pharmaceutical Design, 2018
The neonatal population remains one of the populations in which appropriate dosing regimens are still lacking, resulting in a large off-label or unlicensed use. Clinical research in these small infants remains a challenge, which sparks the need for modeling and simulation as an additional tool for neonatal drug research.The use of physiologically based
Robin, Michelet, Jan Van, Bocxlaer, An, Vermeulen   +2 more
openaire   +2 more sources

Sensitivity Analysis- Theory and PBPK Applications

2021
Presentation to the OECD, Paris (Virtual Meeting Test on April 30th, 2021 - Final presentation on May 10, 2021)Search for CCTE records in EPA s Science Inventory by typing in the title at this link.https://cfpub.epa.gov/si/si_public_search_results.cfm?advSearch=true&showCriteria=2&keyword=CCTE&TIMSType=&TIMSSubTypeID=&epaNumber ...
openaire   +1 more source

A PBPK model for midazolam in four avian species

Journal of Veterinary Pharmacology and Therapeutics, 2009
A physiologically based pharmacokinetic (PBPK) model was developed for midazolam in the chicken and extended to three other species. Physiological parameters included organ weights obtained from 10 birds of each species and blood flows obtained from the literature. Partition coefficients for midazolam in tissues vs.
K A, Cortright, S E, Wetzlich, A L, Craigmill   +2 more
openaire   +2 more sources

Assessing interindividual variability by Bayesian-PBPK modeling

Drug Discovery Today: Disease Models, 2016
The description of interindividual variability and the ADME-related sources of such variability (ADME: absorption, distribution, metabolization, excretion) is an essential element in clinical drug development to identify potentially relevant subgroups of non-responders or high-risk patients.
Markus Krauss, Andreas Schuppert
openaire   +1 more source

PBPK

2022
openaire   +1 more source

Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective

Pharmaceutical Research, 2022
Wen Lin, Jashvant D Unadkat, Tycho Heimbach   +2 more
exaly  

Applications of PBPK/PBBM modeling in generic product development: An industry perspective

Journal of Drug Delivery Science and Technology, 2022
Sivacharan Kollipara, Tausif Ahmed
exaly